Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET)
 
To cite this article:  Blood Transfus 2021; DOI 10.2450/2021.0117-21
DOI:  10.2450/2021.0117-21
Published online:  15/04/2021
Authors
Paolo Gresele, Marco Marietta, Walter Ageno, Rossella Marcucci, Laura Contino, Marco P. Donadini, Laura Russo, Giovanni L. Tiscia, Gualtiero Palareti, Armando Tripodi, Pier Mannuccio Mannucci, Valerio De Stefano
Preview
ChAdOx1 nCOV-19 (Vaxzevria) is a vaccine against SARS-CoV-2 infection (COVID-19) developed by Oxford University and AstraZeneca that uses a replication-deficient chimpanzee adenoviral vector (ChAdOx1) containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene1.
Over the last few weeks, there have been several reports of thromboembolic events in subjects who had been administered Vaxzevria in the previous weeks. This led several European countries to decide to suspend its administration or, more recently, to limit it to subjects over 60 years of age2,3. [ … ]

 
Full Text Download Home Back
          
Share this article: